Atopic dermatitis late-breakers from EADV 2026 in Vienna are the focus of this Dermatology Times interview with Christopher Bunick, MD, PhD, associate professor of dermatology at Yale School…
Atopic dermatitis (AD) affects more than 31 million people in the United States, about 1 in 10, and it remains underestimated and underappreciated for its impact. The State…
In an interview with Targeted Oncology, Daniel Heng, MD, of the University of Calgary, discusses the recent FDA approval of belzutifan (Welireg) plus lenvatinib (Lenvima) for patients with…
Cytokines and chemokines as a possible biomarker in atopic dermatitis Kenji Kabashima MD PhD | Kyoto, Japan Professor, Department of Dermatology Kyoto University Graduate School of Medicine
Eric Simpson, MD, MCR, of the Department of Dermatology at Oregon Health & Science University, discusses 16-week interim data from a phase 2 trial of tilrekimig (PF-07275315). Tilrekimig…
In his first interview about his book “Ghosts in the Blood,” world-renowned hematologist/oncologist and CLL researcher Jeff Sharman, MD, takes us on a fascinating journey through the history…
When it comes to CLL/SLL treatment, what’s the difference between BTK inhibitors and BCL-2 inhibitors? Understanding how these treatment approaches work and how they fit into the treatment…
Chromosomes, FISH, and Why Cytogenetics Matter in CLL This episode explains how chromosome analysis helps predict prognosis in chronic lymphocytic leukemia, starting with the basics of how chromosomes…
Empowering You – Treating Locally Advanced Renal Cell Carcinoma The Kidney Cancer Association and Mayo Clinic held a virtual education event for patients and caregivers on January 31,…
Join us for an informative webinar featuring Dr. Jennifer Woyach as she provides an overview of the current CLL treatment landscape and the many options available to patients…
